UY39297A - Compuestos y métodos para reducir la expresión de kcnt1 - Google Patents

Compuestos y métodos para reducir la expresión de kcnt1

Info

Publication number
UY39297A
UY39297A UY0001039297A UY39297A UY39297A UY 39297 A UY39297 A UY 39297A UY 0001039297 A UY0001039297 A UY 0001039297A UY 39297 A UY39297 A UY 39297A UY 39297 A UY39297 A UY 39297A
Authority
UY
Uruguay
Prior art keywords
compounds
methods
kcnt1
pharmaceutical compositions
expression
Prior art date
Application number
UY0001039297A
Other languages
English (en)
Inventor
Jafar-nejad Paymaan
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of UY39297A publication Critical patent/UY39297A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan compuestos, métodos y composiciones farmacéuticas para reducir la cantidad o actividad del ARN de KCNT1 en una célula o sujeto, y en determinadas circunstancias reducir la cantidad de proteína de KCNT1 en una célula o un sujeto. Estos compuestos, métodos y composiciones farmacéuticas son útiles para mejorar al menos un síntoma o característica de una afección neurológica. Dichos síntomas y características incluyen convulsiones, encefalopatía y anomalías del comportamiento. Los ejemplos no taxativos de afecciones neurológicas que se benefician de estos compuestos, métodos y composiciones farmacéuticas son la epilepsia de la infancia con crisis focales migratorias (EIMFS).
UY0001039297A 2020-06-25 2021-06-25 Compuestos y métodos para reducir la expresión de kcnt1 UY39297A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063044345P 2020-06-25 2020-06-25
US202063079438P 2020-09-16 2020-09-16

Publications (1)

Publication Number Publication Date
UY39297A true UY39297A (es) 2021-12-31

Family

ID=79281885

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039297A UY39297A (es) 2020-06-25 2021-06-25 Compuestos y métodos para reducir la expresión de kcnt1

Country Status (6)

Country Link
US (1) US20240229042A1 (es)
EP (1) EP4171576A2 (es)
JP (1) JP2023533153A (es)
CN (1) CN115701998A (es)
UY (1) UY39297A (es)
WO (1) WO2021263082A2 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048787A1 (en) * 2000-06-14 2002-04-25 Ming-Hui Wei Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US20070059710A1 (en) * 2004-02-27 2007-03-15 Applera Corporation Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2018227247A1 (en) * 2017-06-13 2018-12-20 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1

Also Published As

Publication number Publication date
WO2021263082A3 (en) 2022-02-10
JP2023533153A (ja) 2023-08-02
CN115701998A (zh) 2023-02-14
WO2021263082A2 (en) 2021-12-30
EP4171576A2 (en) 2023-05-03
US20240229042A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
CO2021013371A2 (es) Compuestos y métodos para reducir la expresión de kcnt1
CO2020015256A2 (es) Compuestos y métodos para la reducción de la expresión de lrrk2
Greenwood et al. Dendritic and mitochondrial changes during glutamate excitotoxicity
BR112015014729A2 (pt) estrutura côncava, colheitadeira e método de processamento de uma cultura agrícola
Meyer et al. Skeletal muscle fibrosis develops in response to desmin deletion
PE20211783A1 (es) Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos
CO2019003729A2 (es) Compuestos y métodos para reducir de la expresión de atxn3
AR084559A1 (es) Uso del fitocanabinoide canabidiol (cbd) en combinacion con una droga antiepileptica estandar (saed) en el tratamiento de la epilepsia
DOP2011000114A (es) “compuestos de 9h-purin-6-aminoalquilo que expanden las celulas madre hematopoyeticas
CO6251331A2 (es) Inhibicion de arni de expresion de alfa-enac
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
Alloh et al. Effect of economic and security challenges on the Nigerian health sector
SV2011003807A (es) Composiciones y metodos de uso para anticuerpos terapeuticos
UY37967A (es) Compuestos y métodos para la reducción de la expresión de snca
CO2021016480A2 (es) Células t genomodificadas
UY39297A (es) Compuestos y métodos para reducir la expresión de kcnt1
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CO2021012796A2 (es) Compuestos y métodos para modular ube3a-ats
PE20220003A1 (es) Metodo para la prediccion de eficacia del tratamiento de hemoglobinopatia
Shen et al. Can glial cells save neurons in epilepsy?
AR122744A1 (es) Compuestos y métodos para reducir la expresión de kcnt1
CO2023002128A2 (es) Compuestos y métodos para modular el scn2a
GB201120642D0 (en) Bone broach and method of manufacturing a bone broach
EA202192527A1 (ru) Соединения и способы для снижения экспрессии kcnt1
Lee et al. An study on measures of regulation reform for disaster reduction in steep slopes